Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake

Nuclear Medicine and Biology

Volumn 36, Issue 3, 2009, Pages 335-342

  Monazzam, Azita ^a,b   Razifar, Pasha ^b,c   Ide, Susan ^d   Rugaard Jensen, Michael ^e   Josephsson, Raymond ^a   Blomqvist, Carl ^a   Langström, Bengt ^f   Bergström, Mats ^g  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b BIACORE AB   (Sweden)

^c GE HEALTHCARE   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Department of Biochemistry and Organic Chemistry ^*  (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Growth inhibition; HSP90; Multicellular spheroids; Positron Emission Tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; CHOLINE; FLUORODEOXYGLUCOSE F 18; HEAT SHOCK PROTEIN 90 INHIBITOR; METHIONINE; NVP AUY 922; THYMIDINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CULTURE; CELL VOLUME; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG SCREENING; GLIOBLASTOMA; HUMAN; HUMAN CELL; POSITRON EMISSION TOMOGRAPHY; TUMOR GROWTH; TUMOR SPHEROID;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RESORCINOLS; SPHEROIDS, CELLULAR; TIME FACTORS;

EID: 62549150761     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.12.009     Document Type: Article

References (41)

1. Whitesell L., and Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 5 10 (2005) 761-772
2. Isaacs J.S., Xu W., and Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3 3 (2003) 213-217
3. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425 6956 (2003) 407-410
4. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51 2 (2008) 196-218
5. Hammond L.A., Denis L., Salman U., Jerabek P., Thomas Jr. C.R., and Kuhn J.G. Positron emission tomography (PET): expanding the horizons of oncology drug development. Invest New Drugs 21 3 (2003) 309-340
6. Been L.B., Suurmeijer A.J., Cobben D.C., Jager P.L., Hoekstra H.J., and Elsinga P.H. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31 12 (2004) 1659-1672
7. Kubota K., Yukihiro M., and Ito K. Perspective for imaging of tumor metabolism. Nippon Rinsho 65 2 (2007) 352-356
8. Spaepen K., Stroobants S., Dupont P., Bormans G., Balzarini J., Verhoef G., et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?. Eur J Nucl Med Mol Imaging 30 5 (2003) 682-688
9. Cullinane C., Dorow D.S., Kansara M., Conus N., Binns D., Hicks R.J., et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 65 21 (2005) 9633-9636
10. Andrade R.S., Heron D.E., Degirmenci B., Filho P.A., Branstetter B.F., Seethala R.R., et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 65 5 (2006) 1315-1322
11. Greven K.M., Williams III D.W., McGuirt Sr. W.F., Harkness B.A., D'Agostino Jr. R.B., Keyes Jr. J.W., et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23 11 (2001) 942-946
12. Jana S., and Blaufox M.D. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 36 1 (2006) 51-72
13. Liu D., Hutchinson O.C., Osman S., Price P., Workman P., and Aboagye E.O. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer 87 7 (2002) 783-789
14. Monazzam A., Josephsson R., Blomqvist C., Carlsson J., Langstrom B., and Bergstrom M. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. Breast Cancer Research 9 4 (2007)
15. Monazzam A., Razifar P., Lindhe O., Josephsson R., Langstrom B., and Bergstrom M. A new, fast and semi-automated size determination method (SASDM) for studying multicellular tumor spheroids. Cancer Cell Int 5 (2005) 32
16. Jensen M.R., Schoepfer J., Radimerski T., Massey A., Guy C.T., Brueggen J., et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10 2 (2008) R33
17. Dehdashti F., and Siegel B.A. Neoplasms of the esophagus and stomach. Semin Nucl Med 34 3 (2004) 198-208
18. Ginos J.Z., Cooper A.J., Dhawan V., Lai J.C., Strother S.C., Alcock N., et al. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 28 12 (1987) 1844-1852
19. Kumar R., Maillard I., Schuster S.J., and Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am 42 6 (2004) 1083-1100
20. Pio B.S., Park C.K., Pietras R., Hsueh W.A., Satyamurthy N., Pegram M.D., et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8 1 (2006) 36-42
21. Gallamini A., Hutchings M., Avigdor A., and Polliack A. Early interim PET scan in Hodgkin lymphoma: where do we stand?. Leuk Lymphoma 49 4 (2008) 659-662
22. Omloo J.M., Westerterp M., Sloof G.W., Hoekstra O.S., and van Lanschot J.J. The value of positron emission tomography in the diagnosis and treatment of oesophageal cancer. Ned Tijdschr Geneeskd 152 7 (2008) 365-370
23. Sunaga N., Oriuchi N., Kaira K., Yanagitani N., Tomizawa Y., Hisada T., et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 59 2 (2008) 203-210
24. Schegerin M., Tosteson A.N., Kaufman P.A., Paulsen K.D., and Pogue B.W. Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective. Breast Cancer Res Treat (2008)
25. Vees H., Buchegger F., Albrecht S., Khan H., Husarik D., Zaidi H., et al. 18F-Choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99 6 (2007) 1415-1420
26. McCarthy T.J. Positron emission tomography imaging as a key enabling technology in drug development. Ernst Schering Res Found Workshop 62 (2007) 329-339
27. Kenny L., Coombes R.C., Vigushin D.M., Al-Nahhas A., Shousha S., and Aboagye E.O. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34 9 (2007) 1339-1347
28. Wieder H.A., Geinitz H., Rosenberg R., Lordick F., Becker K., Stahl A., et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 34 6 (2007) 878-883
29. Coope D.J., Cizek J., Eggers C., Vollmar S., Heiss W.D., and Herholz K. Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map. J Nucl Med 48 12 (2007) 1971-1980
30. Giovacchini G., Picchio M., Coradeschi E., Scattoni V., Bettinardi V., Cozzarini C., et al. [(11)C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 35 6 (2008) 1065-1073
31. Terry J., Lubieniecka J.M., Kwan W., Liu S., and Nielsen T.O. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res 11 15 (2005) 5631-5638
32. Fracasso G., and Colombatti M. Effect of therapeutic macromolecules in spheroids. Crit Rev Oncol Hematol 36 2-3 (2000) 159-178
33. Kunz-Schughart L.A., Freyer J.P., Hofstaedter F., and Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 9 4 (2004) 273-285
34. Mueller-Klieser W. Multicellular spheroids. A review on cellular aggregates in cancer research. J Cancer Res Clin Oncol 113 2 (1987) 101-122
35. Santini M.T., Rainaldi G., and Indovina P.L. Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit Rev Oncol Hematol 36 2-3 (2000) 75-87
36. Boyd M., Mairs S.C., Stevenson K., Livingstone A., Clark A.M., Ross S.C., et al. Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy. J Gene Med 4 5 (2002) 567-576
37. Mairs R.J., Ross S.C., McCluskey A.G., and Boyd M. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. J Nucl Med 48 9 (2007) 1519-1526
38. Eshleman J.S., Carlson B.L., Mladek A.C., Kastner B.D., Shide K.L., and Sarkaria J.N. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62 24 (2002) 7291-7297
39. Desoize B., and Jardillier J. Multicellular resistance: a paradigm for clinical resistance?. Crit Rev Oncol Hematol 36 2-3 (2000) 193-207
40. O'Connor K.C. Three-dimensional cultures of prostatic cells: tissue models for the development of novel anti-cancer therapies. Pharm Res 16 4 (1999) 486-493
41. Spector N.L., Xia W., Burris III H., Hurwitz H., Dees E.C., Dowlati A., et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23 11 (2005) 2502-2512